ImmuneOncia Therapeutics Inc is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is principally engaged in the research and development of antibody-based cancer immunotherapy treatments.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
08/09/26	₩2,880.00	-1.03%	82,156
07/09/26	₩2,910.00	+0.69%	97,114
04/09/26	₩2,890.00	+3.03%	104,974
03/09/26	₩2,805.00	-2.09%	135,387
02/09/26	₩2,865.00	-2.88%	142,097

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 08/09/2026			5-day change	1st Jan Change
2,880.00 ^KRW	-1.03%		-2.37%	-77.88%

02-06	ImmuneOncia Therapeutics to conduct capital increase of 120 billion won for operational funds	RE
02/06/25	Immuneoncia Therapeutics, Inc. Announces Interim Results from Phase 1B Clinical Trial of Next-Generation Cd47 Antibody 'Imc-002' At Asco 2025	CI

Market Cap	263B 196M 169M 159M 145M 270M 18.59B 271M 1.88B 727M 9.5B 736M 720M 30.23B	P/E 2024 *	-	P/E 2025	-33.4x
Enterprise Value	240B 179M 154M 144M 132M 246M 16.94B 247M 1.71B 662M 8.66B 671M 656M 27.55B	EV / Sales 2024 *	-	EV / Sales 2025	8,473x
Free-Float	46.19%	Yield 2024 *	-	Yield 2025	-

02-06	ImmuneOncia Therapeutics to conduct capital increase of 120 billion won for operational funds	RE
02/06/25	Immuneoncia Therapeutics, Inc. Announces Interim Results from Phase 1B Clinical Trial of Next-Generation Cd47 Antibody 'Imc-002' At Asco 2025	CI
12/05/25	ImmuneOncia Therapeutics, Inc. has completed an IPO in the amount of KRW 32.905735 billion.	CI

1 day	-1.03%
1 week	-2.37%
Current month	-4.00%
1 month	-9.86%
3 months	-27.09%
6 months	-62.50%
Current year	-77.88%

ImmuneOncia Therapeutics, Inc. Stock

Stocks

A424870

KR7424870004

Biotechnology & Medical Research

Valuation : ImmuneOncia Therapeutics, Inc.

Chart: ImmuneOncia Therapeutics, Inc.

Latest news : ImmuneOncia Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : ImmuneOncia Therapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

1 week	2,755	2,985
1 month	2,755	3,510
Current year	2,300	14,240
1 year	2,300	16,110
3 years	2,300	16,110
5 years	2,300	16,110
10 years	2,300	16,110

Manager	Title	Age	Since
Heung-Tae Kim CEO	Chief Executive Officer	70	21/07/2021
Dong-Hyun Yoon DFI	Director of Finance/CFO	55	26/12/2023
Seong-Yeong Lee CTO	Chief Tech/Sci/R&D Officer	51	-

Director	Title	Age	Since
Heung-Tae Kim BRD	Director/Board Member	70	21/07/2021
Dong-Hyun Yoon BRD	Director/Board Member	55	26/12/2023
Sun-Myeong Baek BRD	Director/Board Member	69	30/03/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IMMUNEONCIA THERAPEUTICS, INC.	-1.03%	-2.37%	-50.09%	-	196M
WUXI APPTEC CO., LTD.	+2.02%	+1.26%	+41.37%	+105.18%	69.19B
ARGENX SE	-0.81%	-4.64%	+31.56%	+74.66%	62.97B
INSMED INCORPORATED	-1.11%	+2.78%	-14.86%	+375.59%	27.27B
BIONTECH SE	-4.92%	-3.22%	-3.90%	-17.87%	24.78B
WUXI BIOLOGICS (CAYMAN) INC.	-1.22%	-1.10%	+29.31%	+14.05%	25.8B
GENMAB A/S	+0.28%	-0.09%	+23.54%	-16.17%	20.11B
PHARMAESSENTIA CORPORATION	+6.04%	+7.25%	+233.25%	+383.12%	18.47B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.23%	-2.19%	-7.89%	+517.41%	14.88B
EXELIXIS, INC.	-2.27%	+1.37%	+53.01%	+160.83%	14.29B
Average	-0.43%	+0.72%	+33.53%	+177.42%	27.8B
Weighted average by Cap.	-0.10%	+0.11%	+37.83%	+140.01%

	2024	2025
Net sales	655M 488K 419K 395K 360K 672K 46.25M 675K 4.68M 1.81M 23.64M 1.83M 1.79M 75.22M	111M 82.88K 71.26K 67.04K 61.18K 114K 7.86M 115K 794K 307K 4.02M 311K 304K 12.78M
Net income	-5.69B -4.24M -3.64M -3.43M -3.13M -5.84M -402M -5.87M -40.62M -15.72M -205M -15.92M -15.57M -654M	-27.36B -20.39M -17.53M -16.5M -15.05M -28.09M -1.93B -28.24M -195M -75.62M -988M -76.58M -74.91M -3.14B
Net Debt	-11.23B -8.37M -7.2M -6.77M -6.18M -11.53M -794M -11.59M -80.22M -31.04M -406M -31.43M -30.75M -1.29B	-23.37B -17.42M -14.97M -14.09M -12.86M -23.99M -1.65B -24.12M -167M -64.58M -844M -65.4M -63.97M -2.69B